

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12P 9/56	A1	(11) International Publication Number: WO 94/23053 (43) International Publication Date: 13 October 1994 (13.10.94)
<p>(21) International Application Number: PCT/DK94/00133</p> <p>(22) International Filing Date: 29 March 1994 (29.03.94)</p> <p>(30) Priority Data: 0390/93 1 April 1993 (01.04.93) DK</p> <p>(71) Applicant (for all designated States except US): NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsvaerd (DK).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): RASMUSSEN, Grethe [DK/DK]; Theklavej 15, st. tv., DK-2400 Copenhagen NV (DK). NIELSEN, Egon [DK/DK]; Niels W. Gades Gade 33, st., DK-2100 Copenhagen Ø (DK). HALKIER, Torben [DK/DK]; Vodroffsvej 4A.7, DK-1900 Frederiksberg C (DK).</p> <p>(74) Common Representative: NOVO NORDISK A/S; Corporate Patents, Novo Allé, DK-2880 Bagsvaerd (DK).</p>		<p>(81) Designated States: AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>
<p>(54) Title: PROTEASE VARIANTS</p> <p>(57) Abstract</p> <p>The present invention relates to protease variants, stabilized towards the inactivation caused by peroxidase systems, in which protease variants a naturally occurring tyrosine residue has been deleted or substituted with a different amino acid residue at one or more positions. The invention also relates to a method of stabilizing a protease towards the inactivation caused by peroxidase systems, and detergent compositions comprising a protease variant of the invention.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

PROTEASE VARIANTS

FIELD OF INVENTION

The present invention relates to protease variants, stabilized towards the inactivation caused by peroxidase systems, in which protease variants a naturally occurring tyrosine residue has been deleted or substituted with a different amino acid residue at one or more positions.

The invention also relates to a method of stabilizing a protease towards the inactivation caused by peroxidase systems, and detergent compositions comprising a protease variant of the invention.

BACKGROUND ART

Peroxidases (E.C. 1.11.1.7) are enzymes that catalyse the oxidation of a substrate (an electron or hydrogen donor) with hydrogen peroxide. Such enzymes are known from microbial, plant and animal origins, e.g. peroxidase from Coprinus cinereus (cf. e.g. EP Patent Application 179,486). They are typically hemoproteins, i.e. they contain a heme as a prosthetic group.

Use of peroxidase together with hydrogen peroxide or a hydrogen peroxide precursor has been suggested e.g. in bleaching of pulp for paper production, in treatment of waste water from pulp production, for improved bleaching in laundry detergents, for dye transfer inhibition during laundering, and for lignin modification, e.g. in particle board production.

Peroxidase systems (also designated POD systems) comprising an enzyme exhibiting peroxidase activity, a source of hydrogen peroxide, and a peroxidase enhancing agent, are used for preventing surplus dyes from coloured fabrics which leach from the fabrics when these are washed from being deposited on other fabrics present in the same wash (this

phenomenon is commonly known as dye transfer). Detergent compositions or wash liquors comprising such peroxidase systems have been described in WO 92/18687 and WO 92/18683.

A major drawback in applying such peroxidase systems to
5 detergent compositions is that the enzymes present in such compositions may be strongly affected by the peroxidase system, thereby hampering the washing performance of the detergent composition.

SUMMARY OF THE INVENTION

10 It has now surprisingly been found that proteolytic enzymes are stabilized towards inactivation caused by peroxidase systems, by deletion or substitution of one or more naturally occurring tyrosine residues with a different amino acid residue.

15 Accordingly, the invention provides a protease variant, in which one or more naturally occurring tyrosine residues have been deleted or substituted with a different amino acid residue.

In another aspect, the invention provides a method of
20 stabilization of a protease towards inactivation caused by a peroxidase system, in which method one or more naturally occurring tyrosine residues are deleted or substituted with a different amino acid residue.

In a further aspect, the invention provides detergent
25 compositions comprising a protease variant of the invention.

In a yet further aspect, the invention provides detergent additives comprising a protease variant of the invention.

BRIEF DESCRIPTION OF DRAWINGS

The present invention is further illustrated by reference
30 to the accompanying drawings, in which:

Fig. 1 shows the residual activity(%) - after 1 min. (black), 5 min. (hatched) and 10 min. (white) - of Subtilisin 309 and Subtilisin 309/V104Y at 35°C in the presence of POD system as described in Example 4.

5

DETAILED DISCLOSURE OF THE INVENTION

The present invention provides novel protease variants, stabilized towards inactivation caused by peroxidase systems.

In the context of this invention, a stabilized protease is a protease variant or a mutated protease having improved
 10 stability towards inactivation caused by peroxidase systems, when compared to the parent enzyme. By a protease variant or a mutated protease is meant a protease obtainable by alteration of a DNA nucleotide sequence of the parent gene or its derivatives. The protease variant or the mutated protease may be
 15 expressed and produced when the DNA nucleotide sequence encoding the enzyme is inserted into a suitable vector in a suitable host organism. The host organism is not necessarily identical to the organism from which the parent gene originated.

20 Amino Acids

As abbreviations for amino acids the following symbols are used:

	A	=	Ala	=	Alanine
	C	=	Cys	=	Cysteine
25	D	=	Asp	=	Aspartic acid
	E	=	Glu	=	Glutamic acid
	F	=	Phe	=	Phenylalanine
	G	=	Gly	=	Glycine
	H	=	His	=	Histidine
30	I	=	Ile	=	Isoleucine
	K	=	Lys	=	Lysine
	L	=	Leu	=	Leucine
	M	=	Met	=	Methionine
	N	=	Asn	=	Asparagine
35	P	=	Pro	=	Proline
	Q	=	Gln	=	Glutamine
	R	=	Arg	=	Arginine

	S	=	Ser	=	Serine
	T	=	Thr	=	Threonine
	V	=	Val	=	Valine
	W	=	Trp	=	Tryptophan
5	Y	=	Tyr	=	Tyrosine
	B	=	Asx	=	Asp (D) or Asn (N)
	Z	=	Glx	=	Glu (E) or Gln (Q)
	X	=	an arbitrary amino acid		
	*	=	deletion or absent amino acid		

10 Peroxidase Activity

In the context of this invention, the enzymatic activity of peroxidases is expressed in "Peroxidase Units" (PODU). In the presence of hydrogen peroxide peroxidases (E.C. 1.11.1.7) catalyse the dehydrogenation of 2,2'-azino-bis(3-ethyl-
 15 benzothiazoline-6-sulfonate) (ABTS). The greenish-blue colour produced is monitored photometrically at 418 nm. One PODU is the amount of enzyme which, under standard conditions (i.e. pH 7.0; hydrogen peroxide as substrate; 0.1 M phosphate buffer; an incubation temp. of 30°C; an incubation time of 3 min. measured
 20 kinetically) catalyses the conversion of 1 μ mol of hydrogen peroxide per minute.

Protease Activity

In the context of this invention, the enzymatic activity of subtilisins was measured using chromogenic substrates.
 25 Incubation of proteases with these substrates results in the cleavage of the substrate and liberation of p-nitroaniline that is detected spectrophotometrically at 405 nm.

Subtilisins are analyzed using the substrate N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide (0.8 mM in 20 mM sodium phosphate buffer, pH 8.5 or 0.8 mM in 20 mM Britton-Robinson
 30 buffer, pH 8.5). The incubation is carried out at 25°C and followed spectrophotometrically for 4 min. The concentration of the protease is chosen so that the liberation of p-nitroaniline is linear during the whole analysis.

Peroxidase Systems

In the context of this invention, a peroxidase system is a system comprising a peroxidase or a compound exhibiting peroxidase activity, a source of hydrogen peroxide, and a peroxidase enhancing agent. Such peroxidase systems have been used for obtaining a dye transfer inhibition and have been described in e.g. International Patent Applications WO 92/18687 and WO 92/18683.

In such a peroxidase system, the peroxidase or the compound exhibiting peroxidase activity may be any peroxidase comprised by the enzyme classification EC 1.11.1.7, or any fragment derived therefrom, exhibiting peroxidase activity, or synthetic or semisynthetic derivatives thereof (e.g. porphyrin ring systems or microperoxidases, cf. e.g. US Patent 4,077,768, EP Patent Application 537,381, International Patent Applications WO 91/05858 and WO 92/16634). Such peroxidases are known from microbial, plant and animal origins.

The peroxidase may be producible by plants (e.g. horseradish or soy bean peroxidase) or microorganisms such as fungi or bacteria. Some preferred fungi include strains belonging to the subdivision Deuteromycotina, class Hyphomycetes, e.g. Fusarium, Humicola, Tricoderma, Myrothecium, Verticillium, Arthromyces, Caldariomyces, Ulocladium, Embellisia, Cladosporium or Dreschlera, in particular Fusarium oxysporum (DSM 2672), Humicola insolens, Trichoderma resii, Myrothecium verrucana (IFO 6113), Verticillium alboatrum, Verticillium dahliae, Arthromyces ramosus (FERM P-7754), Caldariomyces fumago, Ulocladium chartarum, Embellisia allior Dreschlera halodes.

Other preferred fungi include strains belonging to the subdivision Basidiomycotina, class Basidiomycetes, e.g. Coprinus, Phanerochaete, Coriolus or Trametes, in particular Coprinus cinereus f. microsporus (IFO 8371), Coprinus macrorhizus, Phanerochaete chrysosporium (e.g. NA-12) or Trametes

(previously called Polyporus), e.g. T. versicolor (e.g. PR4 28-A).

Further preferred fungi include strains belonging to the subdivision Zygomycotina, class Mycoraceae, e.g. Rhizopus or Mucor, in particular Mucor hiemalis.

Some preferred bacteria include strains of the order Actinomycetales, e.g. Streptomyces spheroides (ATTC 23965), Streptomyces thermoviolaceus (IFO 12382) or Streptoverticillum verticillium ssp. verticillium.

10 Other preferred bacteria include Bacillus pumilus (ATCC 12905), Bacillus stearothermophilus, Rhodobacter sphaeroides, Rhodomonas palustri, Streptococcus lactis, Pseudomonas purrocinia (ATCC 15958) or Pseudomonas fluorescens (NRRL B-11).

Further preferred bacteria include strains belonging to Myxococcus, e.g. M. virescens.

Other potential sources of useful particular peroxidases are listed in Saunders B C et al., Peroxidase, London Butterworths, 1964, pp. 41-43.

The peroxidase may furthermore be one which is produc-
20 ible by a method comprising cultivating a host cell transformed with a recombinant DNA vector which carries a DNA sequence encoding said peroxidase as well as DNA sequences encoding functions permitting the expression of the DNA sequence encoding the peroxidase, in a culture medium under conditions
25 permitting the expression of the peroxidase and recovering the peroxidase from the culture.

Particularly, a recombinantly produced peroxidase is a peroxidase derived from a Coprinus sp., in particular C. macrorhizus or C. cinereus according to WO 92/16634.

30 In the context of this invention, compounds exhibiting peroxidase activity comprise peroxidase active fragments derived from cytochromes, hemoglobin or peroxidase enzymes, and synthetic or semisynthetic derivatives thereof, e.g. iron porphins, iron porphyrins, and iron phthalocyanine and deriva-
35 tives thereof.

In a peroxidase system, the enhancer may be an oxidizable substrate e.g. metal ions or phenolic compounds such as 7-hydroxycoumarin (7HCm), vanillin (VAN), and p-hydroxybenzenesulfonate (pHBS), described in e.g. International Patent
5 Applications WO 92/18683 and WO 92/18687, and Kato M and Shimizu S, Plant Cell Physiol. 1985 26 (7), pp. 1291-1301 (cf. Table 1 in particular), and Saunders B C et al., Peroxidase, London Butterworths, 1964, p. 141 ff. or 2,2'-azino-bis (3-ethylbenzothiazoline-6-sulfonate) (ABTS), described in WO
10 93/00394.

Protease Variants

A protease variant of the invention, stabilized towards inactivation caused by peroxidase systems, may be a variant of any proteolytic enzyme suited for incorporation into deter-
15 gents.

In the context of this invention, such proteolytic enzymes comprise alkaline proteases, subtilisins (e.g. Bacillus lentus proteases, Bacillus amyloliquefaciens proteases and Bacillus licheniformis proteases), trypsin-like proteases (e.g.
20 Fusarium proteases, International Patent Application WO 89/06270), and lytic proteases (e.g. Nocardiosis proteases, International Patent Application WO 88/03947).

Subtilisins

In the context of this invention, a subtilisin is
25 defined as a serine protease produced by gram-positive bacteria or fungi. According to another definition, a subtilisin is a serine protease, wherein the relative order of the amino acid residues in the catalytic triad is Asp - His - Ser (positions 32, 64, and 221, BPN' numbering).

30 Preferred subtilisins are Bacillus lentus proteases, e.g. Subtilisin 309 and Subtilisin 147, Bacillus amyloliquefaciens proteases, e.g. Subtilisin BPN', and Bacillus licheniformis proteases, e.g. Subtilisin Carlsberg.

Amino Acid Numbering

In the context of this invention, a specific numbering of amino acid residue positions in subtilisins is employed. By alignment of the amino acid sequences of various subtilisins along with Subtilisin BPN' it is possible to allot a number to the amino acid residue position in any subtilisin to the number of the analogous amino acid position in Subtilisin BPN' ("BPN' numbering", vide e.g. International Patent Applications WO 89/06279 and WO 91/00345).

10 In describing the various protease variants produced or contemplated according to the invention the following nomenclatures were adapted for ease of reference:

[Original amino acid; Position; Substituted amino acid]

Accordingly, the substitution of tyrosine with phenyl-
15 alanine in position 209 is designated as:

Y209F

Deletion of an aspartic acid at position 36 is indicated as: D36*, and an insertion in such a position is indicated as: 36D for insertion of an aspartic acid in position 36.

20 Multiple mutations are separated by plusses, i.e.:

Y167I+Y209F

representing mutations in positions 167 and 209, substituting tyrosine with isoleucine and phenylalanine, respectively.

If a substitution is made by mutation in e.g. Subtilisin
25 309, the product is designated e.g. "Subtilisin 309/Y209F".

All positions in respect of subtilisins mentioned in this context refer to the BPN' numbers described above.

In a preferred embodiment, the protease variant of the invention is a subtilisin that has been changed in one or more
30 of the following positions: 6, 57, 91, 104, 143, 167, 171, 192, 206, 209, 214, 256, 262, 263, more preferred 104, 167, 171, 192 (BPN' numbering).

In another preferred embodiment, the protease variant of the invention is Subtilisin 309, Subtilisin 147, Subtilisin BPN', or Subtilisin Carlsberg.

Methods of Stabilizing Proteases

5 The present invention provides a method of stabilizing proteolytic enzymes towards inactivation caused by peroxidase systems, by which method one or more naturally occurring tyrosine residues are deleted or substituted with a different amino acid residue.

10 Recombinantly Produced Enzymes

In the past, numerous processes have been developed for the production of polypeptides or proteins by means of the recombinant DNA technology. Mostly used for this purpose are E. coli, Bacillus subtilis, Saccharomyces cerevisiae and different
15 Aspergillus strains, e.g. A. oryzae and A. niger.

Expression of Polypeptides Biosynthetically

Upon transformation of an organism where the intention is production of a polypeptide or a protein, a DNA sequence is introduced into the organism. The sequence contains the coding
20 region of the gene of interest flanked by transcription/-translation start signals and transcription/translation termination signals. The coding region contains units of three base pairs, called codons, which upon translation of the transcribed gene are translated into amino acids, which again
25 are assembled to give the polypeptide of interest.

Introducing Mutations in Polypeptides

By changing one or more specific codons in the coding region and transforming the host microorganism with these new coding regions, new polypeptides can be produced which differ
30 from the original polypeptide by one or more amino acids. Such alterations can be introduced by means of a technique generally

known as "site-directed in vitro mutagenesis". A number of methods have been published. An early method is described by Zoller & Smith, DNA 1984 3 (6) 479-488, and involves use of the single-stranded M13 bacteriophage. A preferred method using PCR
5 (polymerase chain reaction) is described by Nelson & Long, Analytical Biochemistry, 1989 180 147-151. It involves a 3-step generation of a PCR fragment containing the desired mutation by using a chemically synthesized DNA oligonucleotide as one of the primers in the PCR reactions. From the PCR-generated
10 fragment, a DNA fragment carrying the mutation can be isolated by cleavage with restriction enzymes and re-inserted into the expression plasmid. A third mutagenesis method takes advantage of restriction sites in the DNA coding region. By digesting the DNA with restriction enzymes at sites flanking the mutagenesis
15 target, synthesizing a new fragment synthetically containing the desired mutation and cloning this new fragment between the restriction sites, a mutant coding region can be constructed.

All methods are generally applicable to investigations in the field called protein engineering which deals with the
20 development of polypeptides with new or altered characteristics.

Transformation and expression may be accomplished by methods known in the art, e.g. as described in European Patent Application 305,216, which specification is hereby included by
25 reference.

The microorganisms able to produce a stabilized enzyme of this invention can be cultivated by conventional fermentation methods in a nutrient medium containing assimilable carbon and nitrogen together with other essential nutrients,
30 the medium being composed in accordance with the principles of the known art. Purification and recovery of the stabilized enzyme may also be conducted in accordance with methods known per se.

Cloning A Protease Gene

The gene encoding the proteolytic enzyme may be cloned from any Gram-positive bacteria or fungus by various methods well known in the art. First a genomic, and/or cDNA library of DNA must be constructed using chromosomal DNA or messenger RNA from the organism that produces the protease to be studied. Then, if the amino-acid sequence of the protease is known, homologous oligonucleotide probes may be synthesized, labelled, and used to identify protease-encoding clones from a genomic library of bacterial DNA, or from a fungal cDNA library. Alternatively, a labelled oligonucleotide probe containing sequences homologous to protease from another strain of bacteria or fungus could be used as a probe to identify protease-encoding clones, using hybridization and washing conditions of lower stringency.

Yet another method for identifying protease-producing clones would involve inserting fragments of genomic DNA into an expression vector such as a plasmid, transforming protease-negative bacteria with the resulting genomic DNA library, and then plating the transformed bacteria onto agar containing a substrate for protease, such as skim-milk. Those bacteria containing protease-bearing plasmid will produce colonies surrounded by a halo of clear agar, due to digestion of the skim-milk by excreted proteolytic enzyme.

Generation Of Site Directed Mutations In The Protease Gene

Once the protease gene has been cloned and desirable sites for mutagenesis identified, the mutations can be introduced using synthetic oligonucleotides. These oligonucleotides contain nucleotide sequences flanking the desired mutation sites, mutant nucleotides are inserted during oligonucleotide synthesis. In a preferred method, a single stranded gap of DNA, bridging the protease gene, is created in a vector bearing the protease gene. Then the synthetic nucleotide, bearing the desired mutation, is annealed to a homologous portion of the

single-stranded DNA. The remaining gap is then filled in by DNA polymerase I (Klenow fragment), and the construct is ligated using T4 ligase. A specific example of this method is described [Morinaga et al., Biotechnology, 1984 2 646-639]. According to
5 Morinaga et al., a fragment within the gene is removed using restriction endonuclease. The vector/gene, now containing a gap, is then denatured and hybridized to a vector/gene which, instead of containing a gap, has been cleaved with another restriction endonuclease at a site outside the area involved in
10 the gap. A single-stranded region of the gene is then available for hybridization with mutated oligonucleotides, the remaining gap is filled in by the Klenow fragment of DNA polymerase I, the insertions are ligated with T4 DNA ligase, and, after one cycle of replication, a double-stranded plasmid bearing the
15 desired mutation is produced. The Morinaga method obviates the additional manipulation of constructing new restriction sites, and, therefore, facilitates the generation of mutations at multiple sites. US Patent 4,760,025 discloses the introduction of oligonucleotides bearing multiple mutations by performing
20 minor alterations of the cassette. However, an even greater variety of mutations can be introduced at any one time by the Morinaga method, because a multitude of oligonucleotides, of various lengths, can be introduced.

Expression Of Protease Variants

25 According to the invention, a mutated protease gene produced by methods described above, or any alternative methods known in the art, can be expressed, in enzyme form, using an expression vector. An expression vector generally falls under the definition of a cloning vector, since an expression vector
30 usually includes the components of a typical cloning vector, namely an element that permits autonomous replication of the vector in a microorganism independent of the genome of the microorganism, and one or more phenotypic markers for selection purposes. An expression vector includes control sequences

encoding a promoter, operator, ribosome binding site, translation initiation signal, and, optionally, a repressor gene or various activator genes.

To permit the secretion of the expressed protein, 5 nucleotides encoding a "signal sequence" may be inserted prior to the coding sequence of the gene. For expression under the direction of control sequences, a target gene to be treated according to the invention is operably linked to the control sequences in the proper reading frame. Promoter sequences that 10 can be incorporated into plasmid vectors, and which can support the transcription of the mutant protease gene, include but are not limited to the prokaryotic β -lactamase promoter [Villa-Kamaroff, et al., Proc. Natl. Acad. Sci. U.S.A., 1978 75 3727-3731] and the tac promoter [DeBoer, et al., Proc. Natl. Acad. 15 Sci. U.S.A., 1983 80 21-25]. Further references can also be found in "Useful proteins from recombinant bacteria" in Scientific American, 1980 242 74-94.

According to one embodiment, B. subtilis is transformed by an expression vector carrying the mutated DNA. If expression 20 is to take place in a secreting microorganism such as B. subtilis, a signal sequence may follow the translation initiation signal and precede the DNA sequence of interest. The signal sequence acts to transport the expression product to the cell wall where it is cleaved from the product upon secretion. 25 The term "control sequences" as defined above is intended to include a signal sequence, when it is present.

The microorganisms able to produce a stabilized enzyme of this invention can be cultivated by conventional fermentation methods in a nutrient medium containing assimilable 30 carbon and nitrogen together with other essential nutrients, the medium being composed in accordance with the principles of the known art.

The protease variant protein secreted from the host cells may conveniently be recovered from the culture medium by 35 well-known procedures including separating the cells from the

medium by centrifugation or filtration, and precipitating proteinaceous components of the medium by means of a salt such as ammonium sulphate, followed by chromatographic procedures such as ion exchange chromatography, affinity chromatography, or the like.

Nucleotide Sequences, Expression Vectors And Microorganisms

This invention also relates to DNA nucleotide sequences encoding a stabilized protease variant of the invention. The stabilized enzyme variant may be expressed and produced when DNA nucleotide sequence encoding this enzyme is inserted into a suitable vector in a suitable host organism. The host organism is not necessarily identical to the organism from which the parent gene originated.

The invention also relates to expression vectors and host organisms containing a DNA nucleotide encoding a stabilized protease variant of this invention.

Detergent Compositions

According to the invention, the protease variant may typically be a component of a detergent composition. As such, it may be included in the detergent composition in the form of a non-dusting granulate, a stabilized liquid, or a protected enzyme. Non-dusting granulates may be produced, e.g., as disclosed in US 4,106,991 and 4,661,452 (both to Novo Industri A/S) and may optionally be coated by methods known in the art. Examples of waxy coating materials are poly(ethylene oxide) products (polyethyleneglycol, PEG) with mean molar weights of 1000 to 20000, ethoxylated nonylphenols having from 16 to 50 ethylene oxide units; ethoxylated fatty alcohols in which the alcohol contains from 12 to 20 carbon atoms and in which there are 15 to 80 ethylene oxide units; fatty alcohols; fatty acids; and mono- and di- and triglycerides of fatty acids. Examples of film-forming coating materials suitable for application by fluid bed techniques are given in patent GB 1483591. Liquid

enzyme preparations may, for instance, be stabilized by adding a polyol such as propylene glycol, a sugar or sugar alcohol, lactic acid or boric acid according to established methods. Other enzyme stabilizers are well known in the art. Protected
5 enzymes may be prepared according to the method disclosed in EP 238,216.

The detergent composition of the invention may be in any convenient form, e.g. as powder, granules, paste or liquid. A liquid detergent may be aqueous, typically containing up to 70%
10 of water and 0-30% of organic solvent, or nonaqueous.

The detergent composition comprises one or more surfactants, each of which may be anionic, nonionic, cationic, or zwitterionic. The detergent will usually contain 0-50% of anionic surfactant such as linear alkylbenzenesulfonate (LAS),
15 alpha-olefinsulfonate (AOS), alkyl sulfate (fatty alcohol sulfate) (AS), alcohol ethoxysulfate (AEOS or AES), secondary alkanesulfonates (SAS), alpha-sulfo fatty acid methyl esters, alkyl- or alkenylsuccinic acid or soap. It may also contain 0-40% of nonionic surfactant such as alcohol ethoxylate (AEO or
20 AE), carboxylated alcohol ethoxylates, nonylphenol ethoxylate, alkylpolyglycoside, alkyl dimethylamineoxide, ethoxylated fatty acid monoethanolamide, fatty acid monoethanolamide, or polyhydroxy alkyl fatty acid amide (e.g. as described in WO 92/06154).

25 The detergent composition may additionally comprise one or more other enzymes, such as amylase, cellulase, cutinase, lipase, peroxidase, or oxidase.

The detergent may contain 1-65% of a detergent builder or complexing agent such as zeolite, diphosphate, triphosphate,
30 phosphonate, citrate, nitrilotriacetic acid (NTA), ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTMPA), alkyl- or alkenylsuccinic acid, soluble silicates or layered silicates (e.g. SKS-6 from Hoechst). The detergent may also be unbuilt, i.e. essentially free of detergent
35 builder.

The detergent may comprise one or more polymers. Examples are carboxymethylcellulose (CMC), poly(vinylpyrrolidone) (PVP), polyethyleneglycol (PEG), poly(vinyl alcohol) (PVA), polycarboxylates such as polyacrylates, 5 maleic/acrylic acid copolymers and lauryl methacrylate/acrylic acid copolymers.

The detergent may contain a bleaching system which may comprise a H_2O_2 source such as perborate or percarbonate which may be combined with a peracid-forming bleach activator such as 10 tetraacetylenediamine (TAED) or nonanoyloxybenzenesulfonate (NOBS). Alternatively, the bleaching system may comprise peroxy acids of e.g. the amide, imide, or sulfone type.

The enzymes of the detergent composition of the invention 15 may be stabilized using conventional stabilizing agents, e.g. a polyol such as propylene glycol or glycerol, a sugar or sugar alcohol, lactic acid, boric acid, or a boric acid derivative as e.g. an aromatic borate ester, and the composition may be formulated as described in e.g. WO 92/19709 and 20 WO 92/19708.

The detergent may also contain other conventional detergent ingredients such as e.g. fabric conditioners including clays, foam boosters, suds suppressors, anti-corrosion agents, soil-suspending agents, anti-soil redeposition agents, dyes, 25 bactericides, optical brighteners, or perfume.

The pH (measured in aqueous solution at use concentration) will usually be neutral or alkaline, e.g. 7-11.

Particular forms of detergent compositions within the scope of the invention include:

- 1) A detergent composition formulated as a granulate having a bulk density of at least 600 g/l comprising
- linear alkylbenzenesulfonate (calculated as acid) 7 - 12%
 - 5 - alcohol ethoxysulfate (e.g. C₁₂₋₁₈ alcohol, 1-2 EO) or alkyl sulfate (e.g. C₁₆₋₁₈) 1 - 4%
 - alcohol ethoxylate (e.g. C₁₄₋₁₅ alcohol, 7 EO) 5 - 9%
 - 10 - sodium carbonate (as Na₂CO₃) 14 - 20%
 - soluble silicate (as Na₂O, 2SiO₂) 2 - 6%
 - zeolite (as NaAlSiO₄) 15 - 22%
 - sodium sulfate (as Na₂SO₄) 0 - 6%
 - sodium citrate/citric acid 0 - 15%
 - 15 (as C₆H₅Na₃O₇/C₆H₈O₇)
 - sodium perborate (as NaBO₃·H₂O) 11 - 18%
 - TAED 2 - 6%
 - carboxymethylcellulose 0 - 2%
 - polymers (e.g. maleic/acrylic acid copolymer, PVP, PEG) 0 - 3%
 - 20 - enzymes 0 - 5%
 - minor ingredients (e.g. suds suppressors, perfume, optical brightener, photobleach) 0 - 5%
- 25 2) A detergent composition formulated as a granulate having a bulk density of at least 600 g/l comprising
- linear alkylbenzenesulfonate (calculated as acid) 6 - 11%
 - 30 - alcohol ethoxysulfate (e.g. C₁₂₋₁₈ alcohol, 1-2 EO) or alkyl sulfate (e.g. C₁₆₋₁₈) 1 - 3%
 - alcohol ethoxylate (e.g. C₁₄₋₁₅ alcohol, 7 EO) 5 - 9%
 - sodium carbonate (as Na₂CO₃) 15 - 21%

- soluble silicate (as $\text{Na}_2\text{O}, 2\text{SiO}_2$)	1 - 4%
- zeolite (as NaAlSiO_4)	24 - 34%
- sodium sulfate (as Na_2SO_4)	4 - 10%
- sodium citrate/citric acid	0 - 15 %
5 (as $\text{C}_6\text{H}_5\text{Na}_3\text{O}_7/\text{C}_6\text{H}_8\text{O}_7$)	
- carboxymethylcellulose	0 - 2%
- polymers (e.g. maleic/acrylic acid copolymer, PVP, PEG)	1 - 6%
- enzymes	0 - 5%
10 - minor ingredients (e.g. suds suppressors, perfume)	0 - 5%
3) A detergent composition formulated as a granulate having a bulk density of at least 600 g/l comprising	
- linear alkylbenzenesulfonate	
15 (calculated as acid)	5 - 9%
- alcohol ethoxylate (e.g. C_{12-15} alcohol, 7 EO)	7 - 14%
- soap as fatty acid (e.g. C_{16-22})	1 - 3%
20 - sodium carbonate (as Na_2CO_3)	10 - 17%
- soluble silicate (as $\text{Na}_2\text{O}, 2\text{SiO}_2$)	3 - 9%
- zeolite (as NaAlSiO_4)	23 - 33%
- sodium sulfate (as Na_2SO_4)	0 - 4%
- sodium perborate (as $\text{NaBO}_3 \cdot \text{H}_2\text{O}$)	8 - 16%
25 - TAED	2 - 8%
- phosphonate (e.g. EDTMPA)	0 - 1%
- carboxymethylcellulose	0 - 2%
- polymers (e.g. maleic/acrylic acid copolymer, PVP, PEG)	1 - 3%
30 - enzymes	0 - 5%
- minor ingredients (e.g. suds suppressors, perfume, optical brightener)	0 - 5%

- 4) A detergent composition formulated as a granulate having a bulk density of at least 600 g/l comprising
- linear alkylbenzenesulfonate (calculated as acid) 8 - 12%
- 5 - alcohol ethoxylate (e.g. C₁₂₋₁₅ alcohol, 7 EO) 10 - 25%
- sodium carbonate (as Na₂CO₃) 14 - 22%
 - soluble silicate (as Na₂O, 2SiO₂) 1 - 5%
 - zeolite (as NaAlSiO₄) 25 - 35%
- 10 - sodium sulfate (as Na₂SO₄) 0 - 10%
- carboxymethylcellulose 0 - 2%
 - polymers (e.g. maleic/acrylic acid copolymer, PVP, PEG) 1 - 3%
 - enzymes 0 - 5%
- 15 - minor ingredients (e.g. suds suppressors, perfume) 0 - 5%
- 5) An aqueous liquid detergent composition comprising
- linear alkylbenzenesulfonate (calculated as acid) 15 - 21%
- 20 - alcohol ethoxylate (e.g. C₁₂₋₁₅ alcohol, 7 EO or C₁₂₋₁₅ alcohol, 5 EO) 12 - 18%
- soap as fatty acid (e.g. oleic acid) 3 - 13%
 - alkenylsuccinic acid (C₁₂₋₁₄) 0 - 13%
- 25 - aminoethanol 8 - 18%
- citric acid 2 - 8%
 - phosphonate 0 - 3%
 - polymers (e.g. PVP, PEG) 0 - 3%
 - borate (as B₄O₇) 0 - 2%
- 30 - ethanol 0 - 3%
- propylene glycol 8 - 14%

- enzymes 0 - 5%
 - minor ingredients
(e.g. dispersants, suds suppressors,
perfume, optical brightener) 0 - 5%
- 5 6) An aqueous structured liquid detergent composition comprising
- linear alkylbenzenesulfonate
(calculated as acid) 15 - 21%
 - alcohol ethoxylate
10 (e.g. C₁₂₋₁₅ alcohol, 7 EO
or C₁₂₋₁₅ alcohol, 5 EO) 3 - 9%
 - soap as fatty acid (e.g. oleic acid) 3 - 10%
 - zeolite (as NaAlSiO₄) 14 - 22%
 - potassium citrate 9 - 18%
 - 15 - borate (as B₄O₇) 0 - 2%
 - carboxymethylcellulose 0 - 2%
 - polymers (e.g. PEG, PVP) 0 - 3%
 - anchoring polymers as
e.g. lauryl methacrylate/acrylic acid copolymer;
20 molar ratio 25:1; MW 3800 0 - 3%
 - glycerol 0 - 5%
 - enzymes 0 - 5%
 - minor ingredients
(e.g. dispersants, suds suppressors, perfume,
25 optical brighteners) 0 - 5%
- 7) A detergent composition formulated as a granulate having a bulk density of at least 600 g/l comprising
- fatty alcohol sulfate 5 - 10%
 - ethoxylated fatty acid monoethanolamide 3 - 9%
 - 30 - soap as fatty acid 0 - 3%
 - sodium carbonate (as Na₂CO₃) 5 - 10%
 - soluble silicate (as Na₂O, 2SiO₂) 1 - 4%

- zeolite (as NaAlSiO_4) 20 - 40%
- sodium sulfate (as Na_2SO_4) 2 - 8%
- sodium perborate (as $\text{NaBO}_3 \cdot \text{H}_2\text{O}$) 12 - 18%
- TAED 2 - 7%
- 5 - polymers (e.g. maleic/acrylic acid copolymer, PEG) 1 - 5%
- enzymes 0 - 5%
- minor ingredients (e.g. optical brightener, suds suppressors, perfume) 0 - 5%
- 10 8) A detergent composition formulated as a granulate comprising
 - linear alkylbenzenesulfonate (calculated as acid) 8 - 14%
 - ethoxylated fatty acid monoethanolamide 5 - 11%
 - soap as fatty acid 0 - 3%
 - 15 - sodium carbonate (as Na_2CO_3) 4 - 10%
 - soluble silicate (as $\text{Na}_2\text{O} \cdot 2\text{SiO}_2$) 1 - 4%
 - zeolite (as NaAlSiO_4) 30 - 50%
 - sodium sulfate (as Na_2SO_4) 3 - 11%
 - sodium citrate (as $\text{C}_6\text{H}_5\text{Na}_3\text{O}_7$) 5 - 12%
 - 20 - polymers (e.g. PVP, maleic/acrylic acid copolymer, PEG) 1 - 5%
 - enzymes 0 - 5%
 - minor ingredients (e.g. suds suppressors, perfume) 0 - 5%
 - 25 9) A detergent composition formulated as a granulate comprising
 - linear alkylbenzenesulfonate (calculated as acid) 6 - 12%
 - nonionic surfactant, 1 - 4%
 - soap as fatty acid 2 - 6%
 - 30 - sodium carbonate (as Na_2CO_3) 14 - 22%

	- zeolite (as NaAlSiO_4)	18 - 32%
	- sodium sulfate (as Na_2SO_4)	5 - 20%
	- sodium citrate (as $\text{C}_6\text{H}_5\text{Na}_3\text{O}_7$)	3 - 8%
	- sodium perborate (as $\text{NaBO}_3 \cdot \text{H}_2\text{O}$)	4 - 9%
5	- bleach activator (e.g. NOBS or TAED)	1 - 5%
	- carboxymethylcellulose	0 - 2%
	- polymers (e.g. polycarboxylate or PEG)	1 - 5%
	- enzymes	0 - 5%
	- minor ingredients	
10	(e.g. optical brightener, perfume)	0 - 5%
	10) An aqueous liquid detergent composition comprising	
	- linear alkylbenzenesulfonate (calculated as acid)	15 - 23%
	- alcohol ethoxysulfate	
15	(e.g. C_{12-15} alcohol, 2-3 EO)	8 - 15%
	- alcohol ethoxylate (e.g. C_{12-15} alcohol, 7 EO or C_{12-15} alcohol, 5 EO)	3 - 9%
	- soap as fatty acid (e.g. lauric acid)	0 - 3%
20	- aminoethanol	1 - 5%
	- sodium citrate	5 - 10%
	- hydrotrope (e.g. sodium toluenesulfonate)	2 - 6%
	- borate (as B_4O_7)	0 - 2%
	- carboxymethylcellulose	0 - 1%
25	- ethanol	1 - 3%
	- propylene glycol	2 - 5%
	- enzymes	0 - 5%
	- minor ingredients (e.g. polymers, dispersants, perfume, optical brighteners)	0 - 5%

- 11) An aqueous liquid detergent composition comprising
- linear alkylbenzenesulfonate
(calculated as acid) 20 - 32%
 - alcohol ethoxylate
5 (e.g. C₁₂₋₁₅ alcohol, 7 EO
or C₁₂₋₁₅ alcohol, 5 EO) 6 - 12%
 - aminoethanol 2 - 6%
 - citric acid 8 - 14%
 - borate (as B₄O₇) 1 - 3%
 - 10 - polymer (e.g. maleic/acrylic acid copolymer,
anchoring polymers as e.g.
lauryl methacrylate/acrylic acid
copolymer and CMC) 0 - 3%
 - glycerol 3 - 8%
 - 15 - enzymes 0 - 5%
 - minor ingredients (e.g. hydrotropes,
dispersants, perfume, optical brighteners) 0 - 5%
- 12) A detergent composition formulated as a granulate having a
bulk density of at least 600 g/l comprising
- 20 - anionic surfactant (linear
alkylbenzenesulfonate, alkyl sulfate, alpha-
olefinsulfonate, alpha-sulfo fatty acid
methyl esters, alkanesulfonates, soap) 25 - 40%
 - nonionic surfactant
25 (e.g. alcohol ethoxylate) 1 - 10%
 - sodium carbonate (as Na₂CO₃) 8 - 25%
 - soluble silicates (as Na₂O, 2SiO₂) 5 - 15%
 - sodium sulfate (as Na₂SO₄) 0 - 5%
 - zeolite (as NaAlSiO₄) 15 - 28%
 - 30 - sodium perborate (as NaBO₃·4H₂O) 0 - 20%
 - bleach activator (TAED or NOBS) 0 - 5%
 - enzymes 0 - 5%
 - minor ingredients

(e.g. perfume, optical brighteners)

0 - 3%

13) Detergent formulations as described in 1) - 12) where the content of linear alkylbenzenesulfonate - or a part of it - is substituted by alkyl sulfate (C_{12} - C_{18}).

5 14) Detergent formulations as described in 1) - 13) which contain a stabilized or encapsulated peracid either as an additional component or as a substitute for already specified bleach systems.

15) Detergent compositions as described in 3), 7), 9) and 12)
10 where the content of perborate is substituted with percarbonate.

16) Detergent composition formulated as a nonaqueous detergent liquid comprising a liquid nonionic surfactant as e.g. linear alkoxyated primary alcohol, a builder system (e.g. phosphate),
15 enzyme and alkali. The detergent may also comprise anionic surfactant and/or a bleach system.

The protease variant of the invention may be incorporated in concentrations conventionally employed in detergents. It is at present contemplated that, in the detergent
20 composition of the invention, the protease variant may be added in an amount corresponding to 0.001-100 mg of protease variant per litre of wash liquor.

The following examples further illustrate the present invention, and they are not intended to be in any way limiting
25 to the scope of the invention as claimed.

EXAMPLE 1The Peroxidase System

A peroxidase (POD) system used for Dye Transfer Inhibition (DTI), comprising a Coprinus cinereus peroxidase (CiP, 5 obtained according to EP Patent Application 179,486), hydrogen peroxide (H_2O_2), and p-hydroxybenzenesulfonate (pHBS) as peroxidase enhancing agent, was simulated in a sodium phosphate buffer:

[pHBS]: 50 μ M, [H_2O_2]: 200 μ M, [CiP]: 2 PODU/ml, 20 mM 10 sodium phosphate, pH 8.5.

The activity of Subtilisin 309 (Savinase®, supplied by Novo Nordisk A/S Denmark) was investigated after incubation with the peroxidase system for 20 min. at 35°C .

The residual activity of Subtilisin 309 was measured 15 using the substrate N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide, as described above. The stability of the protease was evaluated analytically using concentrations of 40 nM and 400 nM, respectively.

For both concentrations the residual activity of Sub- 20 tilisin 309 was measured to 15% relative to untreated Subtilisin 309. The Subtilisin thus clearly becomes inactivated in the presence of the POD system.

EXAMPLE 2

Subtilisin 309 was incubated with the POD system in 25 the presence of [14 C]-pHBS as described in Example 1. After POD treatment Subtilisin 309 was purified and subjected to further investigation by amino acid analysis and gelfiltration chromatography under denaturing conditions.

Purification of POD Treated Subtilisin 309

30 Two litres of sodium phosphate buffer containing the POD system and Subtilisin 309 in a concentration of 400 nM were

incubated for 20 min. at 35°C. After inactivation the solution was concentrated to 3 ml in Amicon cells using YM10 membranes (Amicon). Further purification was performed on a gelfiltration column; Superdex 75 (16/60) eluted with 0.1 M ammonium acetate. 5 The largest part of the POD treated Subtilisin 309 eluted with a molecular weight slightly higher than untreated Subtilisin 309. The POD treated Subtilisin 309 was concentrated and washed with 10 volumes of Milli Q water in an Amicon cell.

Amino Acid Analysis.

10 Amino acid analysis was carried out in the Applied Biosystems 420A amino acid analysis system according to the manufacturers instructions.

The results from the amino acid analysis are presented in Table 1 below. As can be seen from the Table, the only 15 detectable amino acid that is affected significantly by POD inactivation is tyrosine (Tyr).

POD inactivation of Subtilisin 309 in the presence of [¹⁴C]-pHBS results in radioactive labelling of the enzyme. The covalent nature of this modification has been shown through 20 gelfiltration under denaturing conditions in 2 M urea.

Table 1

Amino acid analysis of Subtilisin 309 and POD inactivated Subtilisin 309.

	POD inactivated Subtilisin 309	Subtilisin 309	Subtilisin 309 (theoretical)
Asx	31	31	27
25 Glx	17	18	15
Ser	34	30	34
Gly	35	36	35

	His	8	7	7
	Arg	10	10	8
	Thr	17	16	17
	Ala	41	39	40
5	Pro	14	14	13
	Tyr	3	8	7
	Val	23	23	25
	Met ^a	2	1	3
	Cys	0	0	0
10	Ile	8	8	9
	Leu	20	19	19
	Phe	2	2	2
	Lys	6	6	5
	Trp ^b	ND ^c	ND ^c	3

15 a Methionine cannot be quantitatively determined following acid hydrolysis

b Tryptophan is completely destroyed during acid hydrolysis

c (ND, not determined).

EXAMPLE 3

20 The stabilization of Subtilisin 309 towards the peroxidase system has been investigated using several variants in which one or more tyrosines were substituted by other amino acid residues.

The peroxidase system was simulated in a Britton-Robinson buffer using 7-hydroxycoumarin (7HCm) as peroxidase enhancing agent:

[7HCm]: 10 μ M, [H₂O₂]: 200 μ M, [CiP]: 2 PODU/ml, 20 mM Britton-Robinson buffer (20 mM sodium acetate, 20 mM sodium borate and 20 mM sodium phosphate), pH 8.5.

The different variants were incubated with the peroxidase system in concentrations varying from 80 to 120 nM. After incubation for 10 min. at 35°C the residual activity of the variants was analyzed using the substrate N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide, as described above. The residual activities were measured relative to untreated variants.

The results are presented in Table 2 below. As can be seen from the Table, the two variants containing substitutions in positions 167, 171, and 192 are significantly stabilized towards the peroxidase system using 7HCm as enhancer.

Table 2

Residual activity of Subtilisin 309 variants after incubation with the POD system for 10 min.

20	Variants	Residual activity (%)
	Sub.309	21 ^a \pm 3
	Sub.309/Y167F+Y171V+Y192F	46 \pm 5
	Sub.309/K235R+K237R+Y263F	31 \pm 4
	Sub.309/Y209F+Y214F	25 \pm 3
25	Sub.309/Y167F+Y171V+Y192F+Y209Q+Y214Q	41 \pm 6

^a mean \pm SD, n=6

EXAMPLE 4

Several of the Subtilisins mentioned above contain a tyrosine residue in position 104. The importance of a tyrosine in this position was investigated using the Subtilisin 309 variant V104Y.

The peroxidase system was simulated in a Britton-Robinson buffer using 7-hydroxycoumarin (7HCm) as peroxidase enhancing agent:

[7HCm]: 5 μ M, [H₂O₂]: 200 μ M, [CiP]: 2 PODU/ml, 20 mM Britton-Robinson buffer (20 mM sodium acetate, 20 mM sodium borate and 20 mM sodium phosphate), pH 8.5.

The proteases were incubated with the peroxidase system in a concentration of 80 nM. After incubation for 1, 5, and 10 min. at 35°C, the residual activities of the proteases were analyzed using the N-succinyl-Ala-Ala-Pro-Phe-p-nitro-anilide substrate, as described above. The residual activities were measured relative to untreated variants.

The results are presented in Fig. 1. After the introduction of an additional tyrosine in position 104, the Subtilisin 309 variant became much more sensitive towards the POD system.

CLAIMS

1. A protease variant, stabilized towards inactivation caused by a peroxidase system comprising a peroxidase or a compound exhibiting peroxidase activity, a source of hydrogen peroxide and a peroxidase enhancing agent, characterized in, that one or more naturally occurring tyrosine residues has/have been deleted or substituted with a different amino acid residue.

2. A protease variant according to claim 1, in which one or more tyrosine residue(s) has/have been substituted with a phenylalanine residue, a leucine residue, an isoleucine residue, a valine residue, a glutamine residue, an asparagine residue, a serine residue, a threonine residue, a glutamic acid residue, or a histidine residue.

3. A protease variant according to either of claims 1-2, being a Bacillus lentus protease variant, preferably a Subtilisin 309 variant or a Subtilisin 147 variant.

4. A protease variant according to either of claims 1-2, being a Bacillus licheniformis protease variant, preferably a Subtilisin Carlsberg variant.

5. A protease variant according to either of claims 1-2, being a Bacillus amyloliquefaciens protease variant, preferably a Subtilisin BPN' variant.

6. A protease variant according to any of claims 3-5, in which protease a tyrosine residue at the following positions: 6, 57, 91, 104, 143, 167, 171, 192, 206, 209, 214, 256, 262, 263, preferably 104, 167, 171, 192, (BPN' numbering), has been deleted or substituted with a different amino acid residue at one or more positions.

7. A method of stabilization of a protease variant towards inactivation caused by a peroxidase system comprising a peroxidase or a compound exhibiting peroxidase activity, a source of hydrogen peroxide and a peroxidase enhancing agent, characterized in, that one or more naturally occurring tyrosine residues is/are deleted or substituted with a different amino acid residue.

8. The method according to claim 7, characterized by substitution of one or more naturally occurring tyrosine residues with a phenylalanine residue, a leucine residue, an isoleucine residue, a valine residue, a glutamine residue, an asparagine residue, a serine residue, a threonine residue, a glutamic acid residue, or a histidine residue.

9. The method according to either of claims 7-8, in which the protease variant is a Bacillus lentus protease variant, preferably a Subtilisin 309 variant or a Subtilisin 147 variant.

10. The method according to either of claims 7-8, in which the protease variant is a Bacillus amyloliquefaciens protease variant, preferably a Subtilisin BPN' variant.

11. The method according to either of claims 7-8, in which the protease variant is a Bacillus licheniformis protease variant, preferably a Subtilisin Carlsberg variant.

12. The method according to any of claims 9-11, in which protease a tyrosine residue at the following positions: 6, 57, 91, 104, 143, 167, 171, 192, 206, 209, 214, 256, 262, 263, preferably 104, 167, 171, 192, (BPN' numbering), has been deleted or substituted with a different amino acid residue at one or more positions.

13. A detergent composition comprising a protease variant according to any of claims 1-6.

14. A detergent composition according to claim 12, which further comprises one or more other enzymes, in particular lipases, amylases, cellulases, oxidases and peroxidases, conventionally incorporated into detergents.

15. A detergent additive comprising a protease variant according to any of claims 1-6, provided in the form of a granulate, preferably a non-dusting granulate, a liquid, in particular a stabilized liquid, a slurry, or a protected enzyme.

1/1




Fig. 1

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 94/00133

A. CLASSIFICATION OF SUBJECT MATTER

IPC5: C12P 9/56

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC5: C12P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO, A1, 9211357 (NOVO NORDISK A/S), 9 July 1992 (09.07.92), see part. page 11 line 19-25 and line 34; page 12 line 15, claims 12-14 and 18-20 --	1-15
X	WO, A1, 9211348 (UNILEVER PLC ET AL.), 9 July 1992 (09.07.92), see part. page 13 line 21-29; page 14 line 25; page 31 and claims 12-14 and 18-20 --	1-15
X	EP, A2, 0251446 (GENENTECH, INC.), 7 January 1988 (07.01.88), see part. page 24 and claims 3 and 5 -- -----	1-12



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

1 July 1994

Date of mailing of the international search report

14 -07- 1994

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Eva Johansson
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

Information on patent family members

28/05/94

International application No.

PCT/DK 94/00133

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A1- 9211357	09/07/92	AU-A- 9121691 EP-A- 0563169	22/07/92 06/10/93
WO-A1- 9211348	09/07/92	EP-A- 0563103	06/10/93
EP-A2- 0251446	07/01/88	AU-B- 614929 AU-A- 7228187 JP-A- 1085075 US-A- 5182204 US-A- 5185258 US-A- 5204015	19/09/91 05/11/87 30/03/89 26/01/93 09/02/93 20/04/93